The United States boasts a thriving pharmaceutical industry, particularly when it comes to the production of active pharmaceutical ingredients (APIs). Among these APIs, tirzepatide has gained significant attention due to its potential in treating type 2 diabetes and other metabolic disorders. Many companies have emerged as leading manufacturers of

A Contract Development and Manufacturing Organization (CDMO) specializing in GMP peptides provides a comprehensive suite of capabilities to support the development and production of therapeutic peptides. These organizations deploy state-of-the-art facilities and qualified personnel to ensure adherence with stringent regulatory requirements, such as